Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Dude51on Mar 06, 2021 3:26pm
250 Views
Post# 32736840

Why bash your bretheren are sackrificing themselfves for us!

Why bash your bretheren are sackrificing themselfves for us!Data from rodent study are strongly positive

Salzman Group studied the effectiveness of R-107 in a rodent model that is very severe and is designed to mimic life-threatening COVID-19 infection. It is characterized by a 90-per-cent mortality rate within seven days, with development of tissue injury in the lung, kidney, pancreas, intestine and liver. This model correlates closely with the human clinical presentation of circulatory shock and multiple organ failure, and thus has served for many decades as a key benchmark in the initial assessment of novel candidate therapeutics for treatment of human sepsis and circulatory shock.

Results from this study were strongly positive, with the active moiety of R-107 demonstrating increased survival from 10 per cent to 90 per cent in septic mice over a week of follow-up. This extraordinary improvement in survival was reflected in the results of blood tests and microscopy showing full tissue protection in all the organs examined, including the liver, lung and small intestine.

The study was conducted by Professor Salvatore Cuzzocrea, president of the University of Messina, and former president of the European Shock Society. A sepsis-like syndrome was created in mice by inoculation with bacterial endotoxin, thereby producing a massive release of pro-inflammatory signalling molecules (cytokines) such as interleukin-1 beta and tumour necrosis factor alpha, which together are able to trigger the full hemodynamic, hematologic and immunologic manifestations typical of the lethal human circulatory shock caused by COVID-19 infection.

<< Previous
Bullboard Posts
Next >>